Universe Pharmaceuticals (UPC) Total Non-Current Liabilities (2024)
Universe Pharmaceuticals (UPC) reported Total Non-Current Liabilities of $2.1 billion for Q3 2024.
Universe Pharmaceuticals (UPC) Total Non-Current Liabilities (2024) Analysis & Trends
Universe Pharmaceuticals (UPC) has 1 years of Total Non-Current Liabilities data on file, last reported at $2.1 billion in Q3 2024.
- For the quarter ending Q3 2024, Total Non-Current Liabilities changed N/A year-over-year to $2.1 billion; the trailing twelve-month figure through Sep 2024 stood at $2.1 billion (changed N/A YoY), and the FY2024 full-year result was $2.1 billion, changed N/A from the prior year.
- Total Non-Current Liabilities was little changed at $2.1 billion in Q3 2024.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.1 billion in Q3 2024 to a low of $2.1 billion in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.14 Bn |